INNODIA Master Protocol for the evaluation of investigational medicinal products in children, adolescents and adults with newly diagnosed type 1 diabetes

Background The INNODIA consortium has established a pan-European infrastructure using validated centres to prospectively evaluate clinical data from individuals with newly diagnosed type 1 diabetes combined with centralised collection of clinical samples to determine rates of decline in beta-cell fu...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Current controlled trials in cardiovascular medicine Ročník 23; číslo 1; s. 414 - 9
Hlavní autoři:	Dunger, David B., Bruggraber, Sylvaine F. A., Mander, Adrian P., Marcovecchio, M. Loredana, Tree, Timothy, Chmura, Piotr Jaroslaw, Knip, Mikael, Schulte, Anke M., Mathieu, Chantal
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	London BioMed Central 18.05.2022 BioMed Central Ltd Springer Nature B.V BMC
Témata:	Adolescent Adult Beneficiaries Beta-cell function Biomarkers Biomedicine C-peptide Care and treatment Charitable foundations Child Complications and side effects COVID-19 Data integrity Data warehouses Decision making Demographic aspects Diabetes Diabetes Mellitus, Type 1 - diagnosis Diabetes Mellitus, Type 1 - drug therapy Drug development Health Sciences Humans Immunology Laboratories Life Sciences Master protocol Medicine Medicine & Public Health Medicine, Botanic Medicine, Herbal Natural history Patient outcomes Peptides Phase 2 Prevention SARS-CoV-2 Statistics for Life Sciences Study Protocol Teenagers Treatment Outcome Trials Type 1 diabetes France Europe Prevention Trials Type 1 diabetes Beta-cell function C-peptide Phase 2 Master protocol
ISSN:	1745-6215, 1745-6215
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!